Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16108484 | 1.00 | RAB9A (1.00) | RAB9ANPC1ALDH1A1HTTLMNA | |
| SCHEMBL5161443 | 0.92 | NPC1 (0.87) | RAB9ANPC1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL16587379 | 0.85 | NPC1 (0.77) | RAB9ANPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL307051 | 0.84 | NPC1 (0.73) | RAB9ANPC1ALDH1A1HTTLMNA | |
| SCHEMBL5168314 | 0.84 | NPC1 (0.73) | RAB9ANPC1ALDH1A1HTTLMNA | |
| SCHEMBL24673320 | 0.84 | NPC1 (0.73) | RAB9ANPC1ALDH1A1HTTLMNA | |
| SCHEMBL23594174 | 0.84 | NPC1 (0.73) | RAB9ANPC1ALDH1A1HTTLMNA | |
| SCHEMBL8396558 | 0.84 | NPC1 (0.73) | RAB9ANPC1ALDH1A1HTTLMNA | |
| SCHEMBL14865782 | 0.84 | EPHX1 (0.76) | RAB9ANPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14860025 | 0.84 | NPC1 (0.74) | RAB9ANPC1ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541592-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541592-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541592-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2012-01-12 | — | — | US | disclosed |
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2012-01-12 | — | — | US | disclosed |
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. | 2011-04-07 | — | — | US | disclosed |
| US-7807700-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807700-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807700-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2007-08-23 | — | — | US | disclosed |
| US-7253196-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253196-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253196-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| WO-2007061661-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1753736-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | Amgen Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2005116002-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD3B1, HSD17B1 | RAB9A 2584/4885NPC1 369/4885ALDH1A1 100/4885 |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | RAB9A 3468/4885NPC1 392/4885ALDH1A1 71/4885 |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | RAB9A 2584/4885NPC1 369/4885ALDH1A1 100/4885 |
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD3B1, HSD17B1 | RAB9A 2584/4885NPC1 369/4885ALDH1A1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.